Cargando…

PROMISCUOUS 2.0: a resource for drug-repositioning

The development of new drugs for diseases is a time-consuming, costly and risky process. In recent years, many drugs could be approved for other indications. This repurposing process allows to effectively reduce development costs, time and, ultimately, save patients’ lives. During the ongoing COVID-...

Descripción completa

Detalles Bibliográficos
Autores principales: Gallo, Kathleen, Goede, Andrean, Eckert, Andreas, Moahamed, Barbara, Preissner, Robert, Gohlke, Björn-Oliver
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7779026/
https://www.ncbi.nlm.nih.gov/pubmed/33196798
http://dx.doi.org/10.1093/nar/gkaa1061
_version_ 1783631247763832832
author Gallo, Kathleen
Goede, Andrean
Eckert, Andreas
Moahamed, Barbara
Preissner, Robert
Gohlke, Björn-Oliver
author_facet Gallo, Kathleen
Goede, Andrean
Eckert, Andreas
Moahamed, Barbara
Preissner, Robert
Gohlke, Björn-Oliver
author_sort Gallo, Kathleen
collection PubMed
description The development of new drugs for diseases is a time-consuming, costly and risky process. In recent years, many drugs could be approved for other indications. This repurposing process allows to effectively reduce development costs, time and, ultimately, save patients’ lives. During the ongoing COVID-19 pandemic, drug repositioning has gained widespread attention as a fast opportunity to find potential treatments against the newly emerging disease. In order to expand this field to researchers with varying levels of experience, we made an effort to open it to all users (meaning novices as well as experts in cheminformatics) by significantly improving the entry-level user experience. The browsing functionality can be used as a global entry point to collect further information with regards to small molecules (∼1 million), side-effects (∼110 000) or drug-target interactions (∼3 million). The drug-repositioning tab for small molecules will also suggest possible drug-repositioning opportunities to the user by using structural similarity measurements for small molecules using two different approaches. Additionally, using information from the Promiscuous 2.0 Database, lists of candidate drugs for given indications were precomputed, including a section dedicated to potential treatments for COVID-19. All the information is interconnected by a dynamic network-based visualization to identify new indications for available compounds. Promiscuous 2.0 is unique in its functionality and is publicly available at http://bioinformatics.charite.de/promiscuous2.
format Online
Article
Text
id pubmed-7779026
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-77790262021-01-07 PROMISCUOUS 2.0: a resource for drug-repositioning Gallo, Kathleen Goede, Andrean Eckert, Andreas Moahamed, Barbara Preissner, Robert Gohlke, Björn-Oliver Nucleic Acids Res Database Issue The development of new drugs for diseases is a time-consuming, costly and risky process. In recent years, many drugs could be approved for other indications. This repurposing process allows to effectively reduce development costs, time and, ultimately, save patients’ lives. During the ongoing COVID-19 pandemic, drug repositioning has gained widespread attention as a fast opportunity to find potential treatments against the newly emerging disease. In order to expand this field to researchers with varying levels of experience, we made an effort to open it to all users (meaning novices as well as experts in cheminformatics) by significantly improving the entry-level user experience. The browsing functionality can be used as a global entry point to collect further information with regards to small molecules (∼1 million), side-effects (∼110 000) or drug-target interactions (∼3 million). The drug-repositioning tab for small molecules will also suggest possible drug-repositioning opportunities to the user by using structural similarity measurements for small molecules using two different approaches. Additionally, using information from the Promiscuous 2.0 Database, lists of candidate drugs for given indications were precomputed, including a section dedicated to potential treatments for COVID-19. All the information is interconnected by a dynamic network-based visualization to identify new indications for available compounds. Promiscuous 2.0 is unique in its functionality and is publicly available at http://bioinformatics.charite.de/promiscuous2. Oxford University Press 2020-11-16 /pmc/articles/PMC7779026/ /pubmed/33196798 http://dx.doi.org/10.1093/nar/gkaa1061 Text en © The Author(s) 2020. Published by Oxford University Press on behalf of Nucleic Acids Research. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Database Issue
Gallo, Kathleen
Goede, Andrean
Eckert, Andreas
Moahamed, Barbara
Preissner, Robert
Gohlke, Björn-Oliver
PROMISCUOUS 2.0: a resource for drug-repositioning
title PROMISCUOUS 2.0: a resource for drug-repositioning
title_full PROMISCUOUS 2.0: a resource for drug-repositioning
title_fullStr PROMISCUOUS 2.0: a resource for drug-repositioning
title_full_unstemmed PROMISCUOUS 2.0: a resource for drug-repositioning
title_short PROMISCUOUS 2.0: a resource for drug-repositioning
title_sort promiscuous 2.0: a resource for drug-repositioning
topic Database Issue
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7779026/
https://www.ncbi.nlm.nih.gov/pubmed/33196798
http://dx.doi.org/10.1093/nar/gkaa1061
work_keys_str_mv AT gallokathleen promiscuous20aresourcefordrugrepositioning
AT goedeandrean promiscuous20aresourcefordrugrepositioning
AT eckertandreas promiscuous20aresourcefordrugrepositioning
AT moahamedbarbara promiscuous20aresourcefordrugrepositioning
AT preissnerrobert promiscuous20aresourcefordrugrepositioning
AT gohlkebjornoliver promiscuous20aresourcefordrugrepositioning